Free tool
FAERS Monitor: Minocin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050649 or its brand name (Minocin, Minocycline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,244
Serious
4,626
88% of reports
Hospitalization
2,522
Death reported
1,747
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,318
- off label use1,216
- drug intolerance988
- pain948
- rheumatoid arthritis946
- nausea829
- rash819
- arthralgia812
- drug hypersensitivity798
- joint swelling762
- fatigue758
- condition aggravated711
- general physical health deterioration705
- pneumonia702
- c-reactive protein increased697
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 79 |
| 2006 | 56 |
| 2007 | 111 |
| 2008 | 92 |
| 2009 | 73 |
| 2010 | 66 |
| 2011 | 106 |
| 2012 | 146 |
| 2013 | 79 |
| 2014 | 77 |
| 2015 | 117 |
| 2016 | 179 |
| 2017 | 214 |
| 2018 | 256 |
| 2019 | 284 |
| 2020 | 320 |
| 2021 | 238 |
| 2022 | 392 |
| 2023 | 417 |
| 2024 | 723 |
| 2025 | 794 |
| 2026 | 334 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| c-reactive protein increasedSignal | 697 | 78.3 | 73.0 | 52,192 |
| drug intoleranceSignal | 988 | 41.4 | 39.2 | 38,724 |
| rheumatoid arthritisSignal | 946 | 33.7 | 31.8 | 29,889 |
| joint swellingSignal | 762 | 25.5 | 23.8 | 17,882 |
| general physical health deteriorationSignal | 705 | 24.6 | 22.9 | 15,916 |
| drug hypersensitivitySignal | 798 | 16.6 | 15.6 | 11,746 |
| condition aggravatedSignal | 711 | 9.4 | 8.8 | 5,394 |
| pneumoniaSignal | 702 | 8.7 | 8.1 | 4,850 |
| arthralgiaSignal | 812 | 7.8 | 7.4 | 4,932 |
| rashSignal | 819 | 7.5 | 7.1 | 4,735 |
| painSignal | 948 | 6.2 | 5.9 | 4,245 |
| off label useSignal | 1,216 | 5.6 | 5.3 | 4,754 |
| nauseaSignal | 829 | 4.2 | 3.9 | 2,098 |
| drug ineffectiveSignal | 1,318 | 4.0 | 3.8 | 3,176 |
| fatigueSignal | 758 | 3.9 | 3.7 | 1,698 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.